key: cord-0890248-rbfb27hl authors: Saad, Sarra; Gammoudi, Rima; Abdessayed, Nihed; Denguezli, Mohamed title: Domperidone‐induced pityriasis rosea‐like drug eruption date: 2022-04-05 journal: Clin Case Rep DOI: 10.1002/ccr3.5674 sha: eb1aff4b0f42709a48314887c4a45ab6dac895a9 doc_id: 890248 cord_uid: rbfb27hl Pityriasis rosea is a common, acute, self limiting inflammatory skin disease. Pityriasis rosea‐like eruptions (PR‐LE) have been reported after drugs. The clinical presentation of PR‐LE can be distinguished from pityriasis rosea. We reporte a 41‐year‐old woman who developed PR‐LE 5 days after administration domperidone. pityriasis rosea-like domperidone drug eruption, pregnancy F I G U R E 1 (A) Erythematous and squamous lesions on the trunk. (B) Without topical treatment, the lesions disappeared two weeks after discontinuing domperione back. Histological examination revealed signs of a drug reaction ( Figure 2 ). The rash disappeared 2 weeks after discontinuing the treatment ( Figure 1B ). Pityriasis rosea is a common, acute, self-limiting inflammatory skin disease due to the endogenous systemic reactivation of human herpesvirus-6 (HHV-6) and/or -7 (HHV-7). Pityriasis rosea-like eruptions (PR-LE) have been reported after drugs. 1 Recently, several cases have been reported of PR-LE after COVID-19 vaccines. 2 The clinical presentation of PR-LE can be distinguished from PR. Herald patch and Prodromal systemic symptoms are absent in PR-LE and lesions are more confluent forming large itchy lesions. 1 Skin reactions to domperidone have been described in two cases represented by systemic lupus-like syndrome and general diffuse erythema with some pustules. The pathophysiology between domperidone and these different reactions is not well understood, it is probably multifactorial and complex. Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them? Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination None. None. Dr Sarra Saad involved in writing the manuscript and submitting the revised article. Dr Rima Gammoudi out the analysis of the manuscript. Dr Nihed Abdessayed involved in writing the histological part of the manuscript. Dr Denguezli Mohamed supervised and approved the revised manuscript. None. Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy. None.ORCID Sarra Saad https://orcid.org/0000-0002-7637-635X